24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Immunotherapy
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
20:56
Ilya Sutskever rules out sale of Safe Superintelligence, takes helm as CEO
16:14
Full list of Israeli high-tech funding rounds in 2025
16:10
IBM-backed Qedma raises $26M Series A to fight quantum computing errors
15:00
Regulatory uncertainty risks pushing Israeli AI startups away from Europe
More stories
Buzz
Most popular
Daily
Weekly
1
Wonderful raises $34M in Seed funding to bring multilingual AI to global call centers
2
Ex-IDF Major General Giora Eiland raising $100M defense fund
3
HP eyes acquisition of beleaguered Landa Digital Printing
4
Verint’s quiet goodbye: How a once-promising Israeli tech star became a modest buyout
5
Avner Netanyahu quietly paid £502,000 cash for an apartment in England using a different name
More news
Immunotherapy
9 stories about Immunotherapy
Cancer Immunotherapy Startup NeoTX Raises $45 Million
20.02.20
|
Adi Pick
NeoTX uses STR to bind genetically engineered bacteria to tumor cells and simultaneously activate the antibacterial response of distant immune cells
Allogenic Immunotherapy Company Adicet Bio Raises $80 Million
02.10.19
|
Meir Orbach
Founded by Israeli chemist Aya Jakobovits, Adicet develops universal immune cell therapies based on gamma delta T cells to treat different forms of cancer
CEO of Nasdaq-Listed Cell Immunotherapy Company Enlivex Steps Down
02.10.19
|
Tzally Greenberg
Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication
Compugen Falls 17% on Employee Cuts Announcement
27.02.19
|
Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen
12.10.18
|
Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18
|
Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen
Kite Pharma’s Cancer Drug Gets Regulatory Nod
19.10.17
|
Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
Kite Pharma Sale Triggers Scientist Quarrel
02.10.17
|
Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur
Cell Immunotherapy Company Raises $8 Million
24.09.17
|
Lilach Baumer
Enlivex Therapeutics Ltd. is a clinical-stage company specializing in autoimmune and inflammatory conditions